Trial Profile

A prospective, noninterventional trial evaluating the safety of ribociclib + endocrine therapy (aromatase inhibitor) in postmenopausal patients with HR+, HER2- metastatic breast cancer (MBC) in the real-world setting.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribociclib (Primary) ; Anastrozole; Aromatase inhibitors; Exemestane; Letrozole
Indications Advanced breast cancer
Focus Adverse reactions
Acronyms REACHAUT

03 Jun 2019 Interim Results (data cutoff 25-Jan-2019, n=61) published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
03 Jun 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com